How the CaMKII protein controls whether brain connections get stronger or weaker
CaMKII Holoenzyme Mechanisms in Opposing Forms of Synaptic Plasticity
Learning how a brain protein called CaMKII decides if nerve connections strengthen or weaken, which could help people with Angelman syndrome and other memory problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11321602 on NIH RePORTER |
What this research studies
I would be reading about work that focuses on CaMKII, a key protein that helps brain cells change their connections in opposite ways (strengthening or weakening). The researchers examine specific molecular switches on CaMKII (such as different phosphorylation sites) and how those changes affect its binding to NMDA receptors like GluN2B. They use laboratory experiments with brain tissue and model systems to see how the holoenzyme structure and modifications direct one outcome versus the other. Understanding these mechanisms aims to point toward molecular targets relevant to conditions such as Angelman syndrome where learning and memory are affected.
Who could benefit from this research
Good fit: People with Angelman syndrome or their caregivers who are willing to be contacted about research updates or possible sample-donation opportunities would be most relevant, though the project is primarily laboratory-based.
Not a fit: Patients seeking immediate clinical treatments are unlikely to receive direct benefit from this basic laboratory research in the short term.
Why it matters
Potential benefit: If successful, this could identify molecular targets that eventually lead to treatments to improve learning and memory for people with Angelman syndrome and related disorders.
How similar studies have performed: Previous neuroscience studies have shown CaMKII is essential for long-term potentiation and depression, but translating detailed holoenzyme mechanisms into therapies remains largely novel.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Bayer, K. Ulrich — University of Colorado Denver
- Study coordinator: Bayer, K. Ulrich
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.